Literature DB >> 2654801

Use of meta-analysis to evaluate tolonium chloride in oral cancer screening.

D Rosenberg1, S Cretin.   

Abstract

This study used meta-analysis, an analytical technique that uses raw data from previous researchers, to estimate the efficacy of screening for oral cancer with tolonium chloride (TCl). TCl, a vital blue dye, selectively stains acid tissue components such as DNA and RNA and has been used for more than 20 years by surgeons to identify suspected cancerous lesions. It has not been routinely used by dentists to screen either general or high-risk populations. Sensitivity and specificity, as well as positive and negative predictive values for the TCl test, were calculated. Sensitivity of TCl ranged from 97.8% to 93.5%, and specificity ranged from 92.9% to 73.3%. It was determined that if TCl is used to screen high-risk populations, the likelihood of a false negative finding is extremely low, whereas false positive results will be relatively numerous. However, given the high sensitivity of the test, the absolute number of false positive tests will be small. Further analysis is needed to evaluate the economic costs of false positives and false negatives, versus the value of identifying true positives at an early stage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2654801     DOI: 10.1016/0030-4220(89)90286-7

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  20 in total

1.  Demographics and efficacy of head and neck cancer screening.

Authors:  Andrew G Shuman; Payam Entezami; Anna S Chernin; Nancy E Wallace; Jeremy M G Taylor; Norman D Hogikyan
Journal:  Otolaryngol Head Neck Surg       Date:  2010-09       Impact factor: 3.497

2.  Toluidine blue color perception in identification of oral mucosal lesions.

Authors:  Pelin Güneri; Joel B Epstein; Selin Ergün; Hayal Boyacioğlu
Journal:  Clin Oral Investig       Date:  2010-03-25       Impact factor: 3.573

Review 3.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

4.  Utility of toluidine blue test in accessing and detecting intra-oral malignancies.

Authors:  Deepti Singh; R K Shukla
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-02

5.  Oral premalignancy: new methods of detection and treatment.

Authors:  Ann Gillenwater; Vali Papadimitrakopoulou; Rebecca Richards-Kortum
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

6.  A comparative analysis of toluidine blue with frozen section in oral squamous cell carcinoma.

Authors:  Montasir Junaid; Moaz M Choudhary; Zain A Sobani; Ghulam Murtaza; Sadaf Qadeer; Naeem S Ali; Mumtaz J Khan; Anwar Suhail
Journal:  World J Surg Oncol       Date:  2012-04-16       Impact factor: 2.754

Review 7.  Diagnostic modalities for squamous cell carcinoma: an extensive review of literature-considering toluidine blue as a useful adjunct.

Authors:  Naveen Chhabra; Shruti Chhabra; Nitin Sapra
Journal:  J Maxillofac Oral Surg       Date:  2014-07-29

8.  Role of Toluidine Blue Staining in Suspicious Lesions of Oral Cavity and Oropharynx.

Authors:  Vidhu Vijayakumar; Deepa Reghunathan; Balakrishnan Edacheriyan; Aswin Mukundan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-07-20

9.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

Authors:  V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S Gutkind
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 10.  A chemiluminescent light system in combination with toluidine blue to assess suspicious oral lesions-clinical evaluation and review of the literature.

Authors:  P W Kämmerer; R K Rahimi-Nedjat; T Ziebart; A Bemsch; C Walter; B Al-Nawas; F P Koch
Journal:  Clin Oral Investig       Date:  2014-06-03       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.